ENTX - Entera Bio Ltd.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
2.3200
-0.0048 (-0.21%)
At close: 9:52AM EDT
Stock chart is not supported by your current browser
Previous Close2.3248
Open2.4200
Bid2.2200 x 1100
Ask2.5000 x 2200
Day's Range2.3200 - 2.5200
52 Week Range1.3500 - 6.4000
Volume1,110
Avg. Volume7,667
Market Cap27.785M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.0490
Earnings DateAug 20, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.80
Trade prices are not sourced from all markets
  • PR Newswire

    Introducing Investors to Breakthrough Hi-tech and Bio-tech Companies: Frost & Sullivan Publishes Q2 Coverage for Investors to Make Informed Decisions

    NEW YORK , Oct. 7, 2019 /PRNewswire/ -- Equity research is published in the framework of Frost's Independent Equity Research Program. This type of equity research is trusted by investors as it is unbiased ...

  • GlobeNewswire

    Entera Bio Reports Positive Results from a Phase 2 PK/PD Study of Oral PTH (1-34) in Patients with Hypoparathyroidism

    Entera Bio Ltd. (ENTX) today announced the presentation of positive results from its pharmacokinetic (PK) and pharmacodynamic (PD) study in patients with hypoparathyroidism treated with its oral parathyroid hormone (PTH) drug [Oral hPTH(1-34)].  The results were presented at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting in Orlando, Florida on September 22, 2019. “Entera’s previous Phase 2 study in hypoparathyroid patients presented in 2016 showed that four times daily (QID) dosing of oral hPTH (1-34) had a positive effect on serum calcium, a reduction in serum phosphate and a reduction in urinary calcium.

  • Such Is Life: How Entera Bio (NASDAQ:ENTX) Shareholders Saw Their Shares Drop 51%
    Simply Wall St.

    Such Is Life: How Entera Bio (NASDAQ:ENTX) Shareholders Saw Their Shares Drop 51%

    Investing in stocks comes with the risk that the share price will fall. Unfortunately, shareholders of Entera Bio Ltd...

  • GlobeNewswire

    Entera Bio to Present at the Ladenburg Thalmann 2019 Healthcare Conference

    Entera Bio Ltd. (ENTX) announced today that Adam Gridley, CEO, and Dr. Phillip Schwartz, President of R&D, will present at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019 at 10:00 am Eastern Time. A live webcast of the presentation will be available via the “Investor Relations” page of the Entera Bio website, www.enterabio.com, or by clicking here.  A replay of the webcast will be archived on Entera website for approximately 45 days following the webcast. Entera Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in orphan indications and other areas with significant unmet medical needs.

  • GlobeNewswire

    Entera Bio Reports Second Quarter 2019 Financial Results and Provides Operating Update

    Phase 2 study for oral PTH in osteoporosis was initiated in June 2019; Data expected in 2020Completed Part 2 of a Phase 2 PK/PD study in hypoparathyroidism patients. Results.

  • ACCESSWIRE

    Entera Bio Ltd. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 20, 2019, 2018 / Entera Bio Ltd. (NASDAQ: ENTX ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 20, 2019 at 8:30 ...

  • GlobeNewswire

    Entera Bio to Announce Second Quarter and Six Months ended June 30, 2019 Financial Results on Tuesday, August 20, 2019

    The Company will host a conference call at 8:30 am Eastern Time to discuss the results and provide a corporate update.  A live audio webcast of the presentation will be available via the “Investor Relations” page of the Entera Bio website, www.enterabio.com, or by clicking here.  A replay of the webcast will be archived on Entera website for approximately 45 days following the call. Entera Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in orphan indications and other areas with significant unmet medical needs. The Company is initially applying its technology to develop an oral formulation of a human parathyroid hormone analog, Oral PTH (1-34), for treatment of hypoparathyroidism and osteoporosis.

  • GlobeNewswire

    Entera Bio Appoints Adam Gridley as Chief Executive Officer

    JERUSALEM, Israel, Aug. 05, 2019 -- Entera Bio Ltd. (Nasdaq: ENTX), announced today the appointment of Adam Gridley as Chief Executive Officer, effective immediately. Phillip.

  • What Type Of Shareholder Owns Entera Bio Ltd.'s (NASDAQ:ENTX)?
    Simply Wall St.

    What Type Of Shareholder Owns Entera Bio Ltd.'s (NASDAQ:ENTX)?

    If you want to know who really controls Entera Bio Ltd. (NASDAQ:ENTX), then you'll have to look at the makeup of its...

  • GlobeNewswire

    Entera Announces Initiation of Phase 2 Dose Ranging Study for Oral PTH

    Entera Bio Ltd. (ENTX), announced today that it has initiated a Phase 2 study with its osteoporosis drug candidate EB613, an oral human PTH (1-34) tablet. This double blinded, placebo controlled, dose-ranging study will evaluate three different doses in postmenopausal women with low bone mass. Human PTH (1-34) is a known anabolic treatment currently available as a daily subcutaneous injection, Forteo® (marketed by Eli Lilly®) with a known effect on bone formation biomarkers and bone mineral density (BMD).

  • PR Newswire

    From Injections to Pills - Entera Bio (ENTX): Initiation of Coverage by Frost & Sullivan

    Entera Bio recently entered into a $270 million license agreement with Amgen. Entera Bio's platform technology enables oral therapies based on molecules that would otherwise undergo gastric degradation and have limited or no bioavailability.

  • GlobeNewswire

    Entera Bio Reports First Quarter 2019 Financial Results and Operating Update

    Phase 2b Study for oral PTH in osteoporosis to begin by mid-year 2019Completed Part 2 of a Phase 2 PK/PD study in hypoparathyroidism patients. Data processing and statistical.

  • GlobeNewswire

    Entera Bio Announces 20-F Filing

    Entera Bio Ltd. (ENTX) announced today that it has filed its Annual Report on Form 20-F for the year ended December 31, 2018, with the U.S. Securities and Exchange Commission. Upon request, Entera Bio will send a copy of the Annual Report to any requesting shareholder. Entera Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in orphan indications and other areas with significant unmet medical needs.

  • GlobeNewswire

    Entera Bio Reports 2018 Annual Financial Results and Operating Update

    Positive feedback and guidance from the US FDA regarding development plans for Oral PTH in osteoporosisEntered into research collaboration and license agreement with Amgen,.

  • GlobeNewswire

    Entera Bio to Announce Fourth Quarter and Year Ended December 31, 2018 Financial Results on Thursday, March 28

    JERUSALEM, March 27, 2019 -- Entera Bio Ltd. (Nasdaq: ENTX), announced today that it will report financial results for the fourth quarter and year ended December 31, 2018.

  • GlobeNewswire

    Entera Bio Announces a Transition in the Chief Financial Officer Position

    Entera Bio Ltd. (ENTX), announced today that Mira Rosenzweig, Chief Financial Officer, will be leaving the Company in mid-April 2019 on amicable terms to pursue other professional opportunities closer to her home. Ms. Rosenzweig has confirmed to us that she has no disagreement with the presentation of the Company’s financial statements or accounting policies. “The company appreciates Mira’s dedication and significant contributions to the progress at Entera over the past several years, including the completion of an IPO on the Nasdaq in July 2018.

  • GlobeNewswire

    Entera Bio Announces Positive Feedback and Guidance from the US FDA Regarding its Development Plans for Oral PTH in Osteoporosis

    Entera Bio Ltd. (ENTX), announced today the positive outcome of a pre-IND meeting held with the US Food and Drug Administration (FDA) to discuss the Company’s development plan for Oral PTH for the treatment of osteoporosis. The feedback and guidance were summarized in the formal meeting minutes that Entera subsequently received from the FDA.  In addition to discussing various aspects of the nonclinical and clinical development plan, the meeting focused on the 505 b(2) regulatory pathway and the use of bone mineral density (BMD) rather than fracture incidence as the primary endpoint to support a New Drug Application (NDA). Based on the FDA's response, Entera believes that the Phase 3 study may use BMD as the primary efficacy endpoint and that a fracture endpoint study will not be required.

  • GlobeNewswire

    Entera Bio Reports Third Quarter 2018 Financial Results and Operating Update

    Entered into research collaboration and license agreement with Amgen, potential for up to $270 million in milestone payments, as well as royalties on commercial salesMet with.

  • GlobeNewswire

    Entera Bio Appoints Gerald M. Ostrov to Board of Directors

    JERUSALEM, Jan. 10, 2019 -- Entera Bio Ltd. (Nasdaq: ENTX) announced today the appointment of Gerald M. Ostrov as a new independent director on its Board of Directors,.

  • GlobeNewswire

    Entera Bio and Amgen Enter Strategic Research Collaboration in Inflammatory Disease and Other Serious Illnesses

    Entera Bio Ltd. (ENTX) announced today that it has entered into a research collaboration and license agreement with Amgen in inflammatory disease and other serious illnesses. Entera will use its proprietary drug delivery platform to develop oral formulations for one preclinical large molecule program that Amgen has selected.

  • GlobeNewswire

    Entera Bio Reports Positive Results from Part 1 of a Phase 2 PK/PD Study of Oral PTH (1-34) in Patients with Hypoparathyroidism

    Entera Bio Ltd. (ENTX) announced today that it has received positive results from the first part of its pharmacokinetic (PK) and pharmacodynamic (PD) study in patients with hypoparathyroidism treated with its oral parathyroid hormone (PTH) drug [“Oral PTH (1-34)”]. “The results from Part 1 of the PK/PD study in patients with hypoparathyroidism have confirmed that Oral PTH (1-34) activates biological pathways that PTH is known to regulate.